Publications by authors named "F Gatto"
Immunohistochemistry (IHC) of somatostatin receptor subtype 2 can predict response to first-generation somatostatin receptor ligands (fg-SRLs) in acromegaly. Recently, we validated an open-source digital image analysis (DIA) to quantify somatostatin receptor subtype 2 (SSTR2) expression. We aimed to validate the DIA also on somatostatin receptor subtype 5 (SSTR5) in a new cohort of growth hormone (GH)-secreting pituitary tumors, with IHC performed in a different laboratory, and to correlate fg-SRL response with SSTs expression.
View Article and Find Full Text PDFArticle Synopsis
- * A new method utilizing ultra-high-performance liquid chromatography coupled with triple-quadrupole mass spectrometry (UHPLC-MS/MS) allows for efficient GAG extraction and quantification, processing up to 82 samples in one run.
- * This streamlined process can be completed in approximately 1.5 days, fits standard work shifts, and is precise enough to use GAGs as reliable biomarkers, although it requires specialized knowledge in UHPLC-MS/MS.
Article Synopsis
- Duchenne muscular dystrophy (DMD) is a progressive genetic disorder that currently has no cure, and its management relies on physiotherapy and medications to slow progression.
- Gene therapy presents a promising treatment option but requires a well-organized delivery system, such as the hub-and-spoke model, to effectively support DMD patients in Italy.
- A study mapped existing DMD centers in Italy, evaluated their readiness for gene therapy, and identified areas for improvement, ultimately proposing a flexible organizational model to enhance patient care.
Article Synopsis
- Acromegaly, a condition caused by excessive growth hormone and IGF-1, negatively affects patients' quality of life and is conventionally treated with healthcare-administered therapies, while CAM2029 offers a self-administered option with better convenience and storage.
- A 24-week phase 3 trial involving 72 patients assessed the effectiveness of CAM2029 compared to placebo, focusing on the control of IGF-1 levels and GH.
- Results at Week 22/24 showed that CAM2029 significantly outperformed placebo in controlling IGF-1 and GH levels, leading to improved symptoms, quality of life, and patient satisfaction.
We aimed to investigate the use of free glycosaminoglycan profiles (GAGomes) and cfDNA in plasma to differentiate between lung cancer and benign lung disease, in a cohort of 113 patients initially suspected of lung cancer. GAGomes were analyzed in all samples using the MIRAM Free Glycosaminoglycan Kit with ultra-high-performance liquid chromatography and electrospray ionization triple quadrupole mass spectrometry. In a subset of samples, cfDNA concentration and NGS-data was available.
View Article and Find Full Text PDF